ArticleEnvironmental science & technology2026
Environmentally Safe and Just Pharmacy: A Framework and Action Plan for Operating within the Earth System Boundary for Novel Entities.
Article in Environmental science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative Reduction of Pharmaceutical Hazards in Wastewater among Pilot-Scale Quaternary Treatment Technologies across Seasons.ACS environmental Au · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Active pharmaceutical ingredients (APIs) are essential for global health, yet their use and release into the environment contribute to the transgression of the Earth System Boundary for Novel Entities. This study proposes a novel framework for an Environmentally Safe and Just Pharmacy, establishing 4 overarching criteria and 12 subcriteria designed to ensure that the pharmaceutical lifecycle is environmentally safe and just from a novel entities perspective. Using the extensive expertise of our global author group, we conclude that current practices for API design and development, approval and monitoring, use and disposal are only partially or poorly aligned with our criteria. Key vulnerabilities include a lack of environmental considerations in early-stage drug design, widespread exceedances of environmental concentrations deemed safe to ecosystems, persistent selection for antimicrobial resistance in the environment, and severe data gaps in low- and middle-income countries. We further highlight environmental injustices, particularly for Indigenous and marginalized communities whose cultural identities and livelihoods are compromised by chemical contamination. To address these challenges, we present a 10-point roadmap for a transition to a sustainable future by 2050. This plan includes calls for green chemistry investments, the integration of social and cultural equity into risk assessments, and the global upgrade of treatment and management infrastructure. We emphasize that solutions to pharmaceutical impacts must be culturally sensitive and safeguard the dignity of vulnerable populations to ensure a truly just transition that operates within Earth System Boundaries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.